Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Qiagen ( (QGEN) ).
The Netherlands Authority for the Financial Markets (AFM) has informed Qiagen N.V. of a significant voting rights announcement involving BlackRock, Inc. The details disclosed indicate BlackRock’s indirect real and potential ownership stakes in Qiagen, with capital interest and voting rights distributed across various BlackRock subsidiaries. This announcement highlights BlackRock’s substantial influence within Qiagen, potentially impacting shareholder dynamics and future strategic decisions.
More about Qiagen
Qiagen N.V. operates in the life sciences and molecular diagnostics industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enabling customers to gain valuable insights from the building blocks of life, DNA, RNA, and proteins, enhancing the quality of healthcare and research.
YTD Price Performance: 2.36%
Average Trading Volume: 860,116
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $10.11B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.
